Table of Contents Table of Contents
Previous Page  52 / 54 Next Page
Information
Show Menu
Previous Page 52 / 54 Next Page
Page Background

50

NCCN Guidelines for Patients

®

:

Malignant Pleural Mesothelioma, Version 1.2016

Index

Index

adjuvant treatment

25, 28

anesthesia

15, 16–18, 22–23

anxiety

32

asbestos

10–11, 13

biopsy

13, 15–18, 22–23

cancer cells

8, 10, 15, 22, 24–27

cancer stage

18–20, 25, 28

cell subtype

20, 25, 28

chemotherapy

22, 24–25, 27–28, 30, 32

chest wall

18, 19, 30

computed tomography (CT)

13–16, 18, 22, 24–26,

30

diagnose

10, 15–16, 31

distress

30–32

extrapleural pneumonectomy (EPP)

24–25, 28

gene

8, 10

imaging test

14, 16, 18, 22, 24

laparoscopy

18

lymph node

8, 18–19, 22–23, 25

magnetic resonance imaging (MRI)

18

mediastinoscopy

22

member institutions

49

mesothelium

6–8, 11, 16

metastasis

8

National Comprehensive Cancer Network

1, 2

neoadjuvant treatment

24, 28

panel members

48

pleura

8–11, 14–15, 18–19, 25, 30

pleural biopsy

13, 15

pleural cavity

8, 13, 15, 30

pleural effusion

13, 16, 30, 32

pleural mesothelioma

8, 11, 22, 34

pleurectomy/decortication (P/D)

24–25, 28

positron emission tomography (PET)

22, 24–25,

30

primary treatment

24, 28

radiation therapy

10, 24–26, 28, 30, 32

risk factor

10

side effect

24–25, 27, 30

soluble mesothelin-related peptide (SMRP)

13, 16

staging

18–20

supportive care

19, 27, 30–32

surgery

16, 18, 22–28

symptom

13, 22, 25, 30–31

talc pleurodesis

22, 30, 32

tests

13–20 22–23, 28, 34–36

thoracentesis

13, 15

treatment

10, 18–20, 22–28, 30–31, 34, 36–37

treatment plan

18–20, 25–26

thoracoscopic biopsy

15–16, 18

video-assisted thoracoscopic surgery (VATS)

16,

18